Evaluating a Clinician Support Algorithm to Enhance Implementation of Evidence-Based Chemotherapy-Induced Peripheral Neuropathy Assessment and Management Recommendations
Status: | Recruiting |
---|---|
Conditions: | Cancer, Cancer, Neurology |
Therapuetic Areas: | Neurology, Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 10/20/2018 |
Start Date: | June 4, 2018 |
End Date: | July 31, 2019 |
Contact: | Robert Knoerl, PhD, RN |
Email: | robert_knoerl@DFCI.Harvard.edu |
Phone: | 617-632-6386 |
This research study is evaluating how well a decision support tool works to improve
clinicians' use of recommended chemotherapy-induced peripheral neuropathy (CIPN) assessment
and management strategies in participants receiving chemotherapy.
clinicians' use of recommended chemotherapy-induced peripheral neuropathy (CIPN) assessment
and management strategies in participants receiving chemotherapy.
This research study will test a new clinician decision support tool for the assessment and
management of CIPN. The algorithm is designed to help clinicians make decisions about which
strategies to use for the assessment and/or management of CIPN. The investigators need to
recruit participants receiving chemotherapy that is known to cause CIPN to determine how well
the algorithm works to increase clinicians' use of recommended CIPN assessment and management
strategies.
management of CIPN. The algorithm is designed to help clinicians make decisions about which
strategies to use for the assessment and/or management of CIPN. The investigators need to
recruit participants receiving chemotherapy that is known to cause CIPN to determine how well
the algorithm works to increase clinicians' use of recommended CIPN assessment and management
strategies.
Inclusion Criteria for Patients:
- over 18 years of age,
- completed one infusion of neurotoxic chemotherapy for the treatment of cancer
- has at least three more planned clinic visits associated with neurotoxic chemotherapy
receipt after the day of consent within the next 12 weeks,
- ambulatory,
- signed informed consent,
- willingness to participate in all study activities,
- speaks/reads English,
- receives care from one of the clinicians enrolled in the study.
Exclusion Criteria for Patients:
- prognosis of ≤ three months or
- documented peripheral neuropathy due to other causes (diabetes, alcohol abuse, central
nervous system malignancy, vitamin B deficiency, hereditary, nerve compression
injury).
Inclusion Criteria for Clinicians:
-if they are a Medical Doctor, Physician Assistant, or Nurse Practitioner and provide care
to oncology patients at one of the study sites
Inclusion Criteria for Healthy Controls:
-if they are an adult (18+) who does not have cancer or symptoms of peripheral nerve injury
from any cause and speak/read English
We found this trial at
1
site
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Robert Knoerl, PhD, RN
Phone: 617-632-6386
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials